173 related articles for article (PubMed ID: 14663015)
1. Adenosine A(2A) receptors in nonlocomotor features of Parkinson's disease: introduction.
Ongini E
Neurology; 2003 Dec; 61(11 Suppl 6):S72-3. PubMed ID: 14663015
[No Abstract] [Full Text] [Related]
2. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
[TBL] [Abstract][Full Text] [Related]
3. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
Ramlackhansingh AF; Bose SK; Ahmed I; Turkheimer FE; Pavese N; Brooks DJ
Neurology; 2011 May; 76(21):1811-6. PubMed ID: 21606452
[TBL] [Abstract][Full Text] [Related]
4. Adenosine A2A receptor antagonists in Parkinson's disease: still in the running.
Antonini A; Poewe W
Lancet Neurol; 2014 Aug; 13(8):748-9. PubMed ID: 25008550
[No Abstract] [Full Text] [Related]
5. Parkinson's disease: progression and mortality in the L-DOPA era.
Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
[No Abstract] [Full Text] [Related]
6. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
Chen JF
Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
[TBL] [Abstract][Full Text] [Related]
7. Ropinirole as compared with levodopa in Parkinson's disease.
Hiner BC; Earnhart M
N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001684
[No Abstract] [Full Text] [Related]
8. Current controversies: levodopa in the treatment of Parkinson's disease.
Sharma JC; Vassallo M; Ross IN
Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
[No Abstract] [Full Text] [Related]
9. Levodopa in the treatment of Parkinson's disease: current controversies.
Gerlach M; Reichmann H; Riederer P
Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
[No Abstract] [Full Text] [Related]
10. Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease.
Standaert DG
Neurology; 2003 Dec; 61(11 Suppl 6):S30-1. PubMed ID: 14663006
[No Abstract] [Full Text] [Related]
11. Disease-modifying strategies and challenges in PD: interactive breakout sessions.
Schapira AH
Neurology; 2003 Sep; 61(6 Suppl 3):S56-63. PubMed ID: 14504381
[No Abstract] [Full Text] [Related]
12. Thirty five years of experience in the treatment of Parkinson's disease with levodopa and associations.
Chouza C; Buzó R; Scaramelli A; Romero S; de Medina O; Aljanati R; Dieguez E; Lisanti N; Gomensoro J
J Neural Transm Suppl; 2006; (70):427-31. PubMed ID: 17017563
[No Abstract] [Full Text] [Related]
13. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Jones N; Bleickardt C; Mullins D; Parker E; Hodgson R
Brain Res Bull; 2013 Sep; 98():163-9. PubMed ID: 23838432
[TBL] [Abstract][Full Text] [Related]
14. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Chen JF; Fredduzzi S; Bastia E; Yu L; Moratalla R; Ongini E; Schwarzschild MA
Neurology; 2003 Dec; 61(11 Suppl 6):S74-81. PubMed ID: 14663016
[TBL] [Abstract][Full Text] [Related]
15. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.
Kulisevsky J; Poyurovsky M
Eur Neurol; 2012; 67(1):4-11. PubMed ID: 22134373
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging drug therapies in the management of Parkinson's disease.
Koller WC; Tolosa E
Neurology; 1998 Jun; 50(6 Suppl 6):S1. PubMed ID: 9633678
[No Abstract] [Full Text] [Related]
17. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions.
Simola N; Morelli M; Pinna A
Curr Pharm Des; 2008; 14(15):1475-89. PubMed ID: 18537671
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment of Parkinson's disease.
Ahlskog JE
Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
[No Abstract] [Full Text] [Related]
19. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia.
Vidal EI; Fukushima FB; Valle AP; Villas Boas PJ
J Am Geriatr Soc; 2013 Jan; 61(1):170-2. PubMed ID: 23311565
[No Abstract] [Full Text] [Related]
20. Evaluation of cerebral vasomotor reactivity in Parkinson's disease: is there any association with orthostatic hypotension?
Zamani B; Mehrabani M; Fereshtehnejad SM; Rohani M
Clin Neurol Neurosurg; 2011 Jun; 113(5):368-72. PubMed ID: 21247685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
